Schering Expects Earnings Decline In Second Half, Despite Solid Start To 2006
Executive Summary
Schering-Plough is bracing for a slowdown in the second half of 2006 as it increases its R&D spend and anticipates a drop off in sales for its seasonal products
You may also be interested in...
Schering-Plough To Hone Its Edge In “Build The Base” Phase
Schering-Plough is in a strong financial position for deal-making as it moves into the "build the base" phase of its restructuring initiative, where the firm is actively looking for acquisitions to bolster its R&D portfolio, CEO Fred Hassan said during the company's third quarter earnings call Oct. 20
Schering-Plough To Hone Its Edge In “Build The Base” Phase
Schering-Plough is in a strong financial position for deal-making as it moves into the "build the base" phase of its restructuring initiative, where the firm is actively looking for acquisitions to bolster its R&D portfolio, CEO Fred Hassan said during the company's third quarter earnings call Oct. 20
In The Eye Of The Storm? Merck’s Quarter Is Bright, But Vioxx Cloud Looms
Efforts to reinvigorate Merck's pipeline, cut costs and restore earnings growth paid off in the first quarter as the drug maker reignited investor enthusiasm